AffiliationCancer Research Campaign Department of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractRecombinant purified human haemopoietic growth factors are available for clinical trials and some have been licensed for therapeutic use. Some haemopoietic lineages (erythroid, neutrophilic, monocyte-macrophagic) can be selectively stimulated in order to ameliorate the cytopenias that follow cytotoxic treatment, or that characterize some haematological syndromes, and to stimulate mature cell function. Advances in the knowledge of receptor-ligand interactions and of transduction mechanisms, plus the production of synthetic or mutant molecules that may mimic, potentiate or antagonize the effects of the natural growth factors, should make novel therapeutic approaches possible.
CitationColony-stimulating factors in the clinic. 1992, 3 (6):687-92 Curr. Opin. Biotechnol.
JournalCurrent Opinion in Biotechnology
- The promise of colony-stimulating factors in clinical practice.
- Authors: Glaspy JA, Ambersley JM
- Issue date: 1990 Jan-Feb
- Treatment of a marrow stem-cell disorder with granulocyte colony-stimulating factor.
- Authors: Quesenberry PJ
- Issue date: 1989 May 18
- Early clinical trials with colony-stimulating factors.
- Authors: Morstyn G, Lieschke GJ, Cebon J, Dührsen U, Villeval JL, Sheridan W, McGrath K, Layton JE
- Issue date: 1989
- Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor.
- Authors: Morstyn G, Lieschke GJ, Sheridan W, Layton J, Cebon J, Fox RM
- Issue date: 1989 Apr
- [Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children].
- Authors: Balwierz W, Moryl-Bujakowska A, Balwierz A, Pawińska K
- Issue date: 2006